<DOC>
	<DOCNO>NCT01531777</DOCNO>
	<brief_summary>RATIONALE : Apatinib tyrosin-inhibitor agent target vascular endothelial growth factor receptor ( VEGFR ) , 's anti-angiogenesis effect view preclinical test . The investigator ' phase I study show drug 's toxicity manageable . PURPOSE : 1 . Studying well Apatinib work treat patient . 2 . Finding efficacy safety 500 mg 750mg Apatinib . 3 . Pharmacokinetics/Pharmacodynamics ( PK/PD ) . 4 . Exploring new outcome measure antiangiogenic drug .</brief_summary>
	<brief_title>Dose Finding Pharmacokinetics/Pharmacodynamics Study Apatinib Treatment Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>≥ 18 ≤ 70 year age Histological confirm advanced metastatic colorectal Cancer，at least one measurable lesion , large 10 mm diameter spiral CT scan ( scan layer ≤ 5 mm ) Have fail ≥ 2 line chemotherapy Life expectancy 3 month ECOG performance scale ≤ 1 Duration last therapy 6 week nitroso mitomycin More 4 week operation , radiotherapy cytotoxic agent Adequate hepatic , renal , heart , hematologic function ( platelet &gt; 80 × 10E+9/L , neutrophil &gt; 1.5 × 10E+9/L , serum creatinine ≤ 1×upper limit normal ( ULN ) , bilirubin &lt; 1.25 ULN , serum transaminase ≤ 2.5× ULN ) Child bear potential , negative urine serum pregnancy test result initiate apatinib , must agree commit use reliable method birth control duration study 8 week last dose test article . Male : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 8 week last dose test article . Signed date informed consent . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . History malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Pregnant lactate woman Preexisting uncontrolled hypertension define 140/90 mmHg despite use single medical therapy , class I ( NCI CTCAE 3.0 ) myocardial ischemia , arrhythmia ( include QTcF : male ≥ 450 m , female ≥ 470 m ) , cardiac insufficiency myocardial ischemia , arrhythmia , cardiac insufficiency Before time , second malignancy except cure basal cell carcinoma skin carcinoma insitu uterine cervix Any factor influence usage oral administration Evidence CNS metastasis URT : urine protein ≥ ( ++ ) &gt; 1.0 g 24 h PT , APTT , TT , Fbg abnormal , hemorrhagic tendency ( eg . active peptic ulcer disease ) receive therapy thrombolysis anticoagulation Abuse drug Certain possibility gastric intestine hemorrhage Less 4 week last clinical trial Viral hepatitis type B type C Prior VEGFR inhibitor treatment Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Advanced Colorectal Cancer</keyword>
</DOC>